Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

 Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

Shots:

  • Abbott received a CE mark for asymptomatic testing and self-swabbing using its Panbio COVID-19 Ag test to detect SARS-CoV-2. Abbott has shipped 200M test to 120 countries globally
  • The test is approved with a patient-friendly and minimally invasive nasal swab, i.e. patients can self-administer sample collection under an HCP’s supervision and delivers results in 15mins
  • The test has demonstrated 93.8% sensitivity & 100% specificity in asymptomatic people with high viral loads. Additionally, Abbott will offer the NAVIC mobile app allowing people to display negative results for proof of testing and Sympheos for surveillance management to understand epidemiological trends

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Medical Product Outsourcing

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post